Cardiovascular Imaging Research Center and Core Lab, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Valve Science Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
JAMA Cardiol. 2022 Sep 1;7(9):924-933. doi: 10.1001/jamacardio.2022.2108.
Chronic aortic regurgitation (AR) causes left ventricular (LV) volume overload, which results in progressive LV remodeling negatively affecting outcomes. Whether cardiac magnetic resonance (CMR) volumetric quantification can provide incremental risk stratification over standard clinical and echocardiographic evaluation in patients with chronic moderate or severe AR is unknown.
To compare LV remodeling measurements by CMR and echocardiography between patients with and without heart failure symptoms and to verify the association of remodeling measurements of patients with chronic moderate or severe AR but no or minimal symptoms with clinical outcomes receiving medical management.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study included consecutive patients with at least moderate chronic native AR evaluated by 2-dimensional transthoracic echocardiography and CMR examination within 90 days from each other between January 2012 and February 2020 at Allina Health System. Data were analyzed from June 2021 to January 2022.
Clinical evaluation and risk stratification by CMR.
The end point was a composite of death, heart failure hospitalization, or progression of New York Heart Association functional class while receiving medical management, censoring patients at the time of aortic valve replacement (when performed) or at the end of follow-up.
Of the 178 included patients, 119 (66.9%) were male, 158 (88.8%) presented with no or minimal symptoms (New York Heart Association class I or II), and the median (IQR) age was 58 (44-69) years. Compared with patients with no or minimal symptoms, symptomatic patients had greater LV end-systolic volume index (LVESVi) by CMR (median [IQR], 66 [46-85] mL/m2 vs 42 [30-58] mL/m2; P < .001), while there were no significant differences by echocardiography (LVESVi: median [IQR], 38 [30-58] mL/m2 vs 27 [20-42] mL/m2; P = .07; LV end-systolic diameter index: median [IQR], 21 [17-25] mm/m2 vs 18 [15-22] mm/m2; P = .17). During the median (IQR) follow-up of 3.3 (1.6-5.8) years, 50 patients with no or minimal symptoms receiving medical management developed the composite end point, which, in multivariate analysis adjusted for age and EuroSCORE II, was independently associated with LVESVi of 45 mL/m2 or greater and aortic regurgitant fraction of 32% or greater, the latter adding incremental prognostic value to CMR volumetric assessment.
In patients with chronic moderate or severe AR, patients presenting with heart failure symptoms have greater LVESVi by CMR than those with no or minimal symptoms. In patients with no or minimal symptoms, CMR quantification of LVESVi and AR severity may identify those at risk of death or incident heart failure and therefore should be considered in the clinical evaluation and decision-making of these patients.
慢性主动脉瓣反流(AR)导致左心室(LV)容量超负荷,导致 LV 进行性重塑,对预后产生负面影响。在慢性中度或重度 AR 患者中,心脏磁共振(CMR)容积定量分析是否比标准临床和超声心动图评估提供额外的风险分层尚不清楚。
比较有和无症状的慢性中度或重度 AR 患者的 CMR 和超声心动图 LV 重塑测量,并验证无症状或仅有轻微症状的慢性中度或重度 AR 患者的重塑测量与接受药物治疗的临床结局之间的相关性。
设计、地点和参与者:这项多中心回顾性队列研究纳入了 2012 年 1 月至 2020 年 2 月期间在 Allina Health System 接受二维经胸超声心动图和 CMR 检查的至少中度慢性原发性 AR 患者,两次检查在 90 天内完成。数据于 2021 年 6 月至 2022 年 1 月进行分析。
CMR 临床评估和风险分层。
终点是接受药物治疗时死亡、心力衰竭住院或纽约心脏协会功能分级进展的复合事件,在主动脉瓣置换术(如进行)或随访结束时对患者进行删失。
在 178 名纳入的患者中,119 名(66.9%)为男性,158 名(88.8%)无症状或仅有轻微症状(纽约心脏协会分级 I 或 II),中位(IQR)年龄为 58(44-69)岁。与无症状患者相比,有症状患者的 CMR 左室收缩末期容积指数(LVESVi)更高(中位数[IQR],66[46-85]ml/m2 与 42[30-58]ml/m2;P<0.001),而超声心动图无显著差异(LVESVi:中位数[IQR],38[30-58]ml/m2 与 27[20-42]ml/m2;P=0.07;LV 收缩末期直径指数:中位数[IQR],21[17-25]mm/m2 与 18[15-22]mm/m2;P=0.17)。在中位(IQR)3.3(1.6-5.8)年的随访期间,50 名无症状或仅有轻微症状的患者接受药物治疗后出现复合终点事件,在多变量分析中,该终点事件与 LVESVi 45ml/m2 或更大以及主动脉瓣反流分数 32%或更大独立相关,后者为 CMR 容积评估增加了额外的预后价值。
在慢性中度或重度 AR 患者中,有心力衰竭症状的患者的 CMR 左室收缩末期容积比无症状或仅有轻微症状的患者大。在无症状或仅有轻微症状的患者中,LVESVi 和 AR 严重程度的 CMR 定量分析可能可以识别出死亡或新发心力衰竭的风险患者,因此应在这些患者的临床评估和决策中考虑。